TY - JOUR
T1 - The burden of diseases, injuries, and risk factors by state in the USA, 1990–2021
T2 - a systematic analysis for the Global Burden of Disease Study 2021
AU - GBD 2021 US Burden of Disease Collaborators
AU - Mokdad, Ali H.
AU - Bisignano, Catherine
AU - Hsu, Johnathan M.
AU - Aldridge, Robert W.
AU - Aravkin, Aleksandr Y.
AU - Brauer, Michael
AU - Bryazka, Dana
AU - Cagney, Jack
AU - Cogen, Rebecca M.
AU - Culbreth, Garland T.
AU - Dai, Xiaochen
AU - Daoud, Farah
AU - Degenhardt, Louisa
AU - Dwyer-Lindgren, Laura
AU - Feigin, Valery L.
AU - Flor, Luisa S.
AU - Fu, Weijia
AU - Gardner, William M.
AU - Haakenstad, Annie
AU - Haile, Demewoz
AU - Hamilton, Erin B.
AU - Hay, Simon I.
AU - Ikuta, Kevin S.
AU - Kassebaum, Nicholas J.
AU - Lim, Stephen S.
AU - Mestrovic, Tomislav
AU - Moberg, Madeline E.
AU - Mougin, Vincent
AU - Naghavi, Mohsen
AU - Novotney, Amanda
AU - Ostroff, Samuel M.
AU - Pasovic, Maja
AU - Rafferty, Quinn
AU - Reiner, Robert C.
AU - Runghien, Tilleye
AU - Schumacher, Austin E.
AU - Sirota, Sarah Brooke
AU - Stafford, Lauryn K.
AU - Vongpradith, Avina
AU - Vos, Theo
AU - Wilkerson, Caroline
AU - Zhang, Meixin
AU - Murray, Christopher J.L.
AU - Boyko, Edward J.
AU - Krishnamoorthy, Vijay
AU - Kochhar, Sonali
AU - Morrison, Shane Douglas
AU - Tram, Khai Hoan
AU - Zia, Hafsa
AU - Ababneh, Hazim S.
AU - Ebrahimi, Alireza
AU - Haj-Mirzaian, Arvin
AU - Liu, X.
AU - Liu, Richard T.
AU - Nguyen, Dang H.
AU - Schuermans, Art
AU - Kim, Min Seo
AU - Abbasgholizadeh, Rouzbeh
AU - Emamverdi, Mehdi
AU - Abdelkader, Atef
AU - Arafa, Elshaimaa A.
AU - Abdelmasseh, Michael
AU - Abiodun, Olugbenga Olusola
AU - Aboagye, Richard Gyan
AU - Adzigbli, Leticia Akua
AU - Bosoka, Samuel Adolf
AU - Dowou, Robert Kokou
AU - Manu, Emmanuel
AU - Abu-Zaid, Ahmed
AU - Almustanyir, Sami
AU - Abukhadijah, Hana J.
AU - Nashwan, Abdulqadir J.
AU - Addo, Isaac Yeboah
AU - Okeke, Sylvester Reuben
AU - Dai, Zhaoli
AU - Lin, Jialing
AU - Adeagbo, Oluwafemi Atanda
AU - Adegboye, Oyelola A.
AU - Adekanmbi, Victor
AU - Lee, Wei Chen
AU - Adeyeoluwa, Temitayo Esther
AU - Ekundayo, Temitope Cyrus
AU - Ogundijo, Oluwaseun Adeolu
AU - Olufadewa, Isaac Iyinoluwa
AU - Afolabi, Aanuoluwapo Adeyimika
AU - Agyemang-Duah, Williams
AU - Ahmad, Shahzaib
AU - Khosla, Atulya Aman
AU - Ganiyani, Mohammad Arfat
AU - Ahmad, Danish
AU - Ahmed, Ayman
AU - Siddig, Emmanuel Edwar
AU - Ahmed, Syed Anees
AU - Bodunrin, Aadam Olalekan
AU - Opejin, Abdulahi
AU - Tumurkhuu, Munkhtuya
AU - Akkaif, Mohammed Ahmed
AU - Akrami, Ashley E.
AU - Shah, Nilay S.
AU - Mhlanga, Laurette
AU - Szeto, Mindy D.
AU - Akter, Ema
AU - Noor, Syed Toukir Ahmed
AU - Hasan, Syed Mahfuz Al
AU - Pourali, Ghazaleh
AU - Al-Aly, Ziyad
AU - Liu, Jie
AU - Martin, Randall V.
AU - van Donkelaar, Aaron
AU - Ta'ani, Omar Al
AU - Al-Ajlouni, Yazan
AU - Phillips, Michael R.
AU - Scarmeas, Nikolaos
AU - Al-Rifai, Rami Hani
AU - Al-Tawfiq, Jaffar A.
AU - Al-Wardat, Mohammad
AU - Alrawashdeh, Ahmad
AU - Khader, Yousef Saleh
AU - Al-Zyoud, Walid Adnan
AU - Alam, Manjurul
AU - Tyrovolas, Stefanos
AU - Albakri, Almaza
AU - Aldhaleei, Wafa A.
AU - Cooper, Leslie Trumbull
AU - Chung, Sheng Chia
AU - Ali, Mohammed Usman
AU - Khan, Mohammad Jobair
AU - Ali, Abid
AU - Ali, Rafat
AU - Ali, Waad
AU - Alqutaibi, Ahmed Yaseen
AU - Alsabri, Mohammed A.
AU - Aly, Hany
AU - E’mar, Abdel Rahman
AU - Amani, Reza
AU - Ardekani, Ali
AU - Bayati, Mohsen
AU - Vardanjani, Hossein Molavi
AU - Pourbabaki, Reza
AU - Amegbor, Prince M.
AU - Peprah, Emmanuel K.
AU - Benzian, Habib
AU - Cortese, Samuele
AU - Amindarolzarbi, Alireza
AU - Boppana, Sri Harsha
AU - Hinneh, Thomas Kwadwo
AU - Hundie, Tsegaye Gebreyes
AU - Kazemi, Foad
AU - Vervoort, Dominique
AU - Zhang, Haijun
AU - Jamshidi, Elham
AU - Melese, Endalkachew Belayneh
AU - Amiri, Sohrab
AU - Hushmandi, Kiavash
AU - Anil, Abhishek
AU - Shamim, Muhammad Aaqib
AU - Singh, Surjit
AU - Saravanan, Aswini
AU - Appiah, Francis
AU - Arabloo, Jalal
AU - Bastan, Mohammad Mahdi
AU - Khosravi, Majid
AU - Moradi-Lakeh, Maziar
AU - Ziafati, Makan
AU - Omar, Hany A.
AU - Arafat, Mosab
AU - Areda, Demelash
AU - Ashina, Sait
AU - Bärnighausen, Till Winfried
AU - Pradhan, Pranil Man Singh
AU - Basu, Sanjay
AU - dos Santos, Florentino Luciano Caetano
AU - Chi, Gerald
AU - Feroze, Abdullah Hamid
AU - Kubeisy, Connor M.
AU - Natto, Zuhair S.
AU - Pigeolet, Manon
AU - Atreya, Alok
AU - Ayalew, Fekadu Belay
AU - Azzam, Ahmed Y.
AU - Babu, Giridhara Rathnaiah
AU - Baghdadi, Soroush
AU - Bagherieh, Sara
AU - Bahramian, Saeed
AU - Rad, Mehrdad Rabiee
AU - Bemanalizadeh, Maryam
AU - Najdaghi, Soroush
AU - Davani, Delaram Narimani
AU - Vakili, Omid
AU - Bahreini, Razieh
AU - Bako, Abdulaziz T.
AU - Elhadi, Muhammed
AU - Bansal, Kannu
AU - Barrow, Amadou
AU - Braithwaite, Dejana
AU - Ding, Delaney D.
AU - Yang, Danting
AU - Beiranvand, Maryam
AU - Diaz, Michael J.
AU - Karanth, Shama D.
AU - Momtazmanesh, Sara
AU - Heidary, Zohreh
AU - Khatami, Fatemeh
AU - Khormali, Moein
AU - Rahimi-Movaghar, Vafa
AU - Shool, Sina
AU - Mafhoumi, Asma
AU - Rad, Elaheh Malakan
AU - Mansouri, Vahid
AU - Shafie, Mahan
AU - Shahbandi, Ataollah
AU - Sharifan, Amin
AU - Tabche, Celine
AU - Batra, Ravi
AU - Batra, Kavita
AU - Sharma, Manoj
AU - Bell, Michelle L.
AU - Etaee, Farshid
AU - Goldust, Mohamad
AU - Li, Wei
AU - Rhee, Taeho Gregory
AU - Pawar, Shrikant
AU - Beloukas, Apostolos
AU - Bennitt, Fiona B.
AU - Beran, Azizullah
AU - Tran, Jasmine T.
AU - Bermudez, Amiel Nazer C.
AU - Mohamed, Mouhand F.H.
AU - Bernstein, Robert S.
AU - Fasanmi, Abidemi Omolara
AU - Sleet, David A.
AU - Beyene, Habtamu B.B.
AU - Schlaich, Markus P.
AU - Beyene, Kebede A.
AU - Bhagavathula, Akshaya Srikanth
AU - Bhala, Neeraj
AU - Bhargava, Ashish
AU - Bhaskar, Sonu
AU - Bhat, Vivek
AU - Borhany, Hamed
AU - Ghadimi, Delaram J.
AU - Ghotbi, Elena
AU - Halimi, Aram
AU - Mohammadzadeh, Ibrahim
AU - Rahmanian, Mohammad
AU - Sabour, Siamak
AU - Safari, Mehdi
AU - Boxe, Christopher
AU - Hossain, Md Mahbub
AU - Pashaei, Ava
N1 - Publisher Copyright:
© 2024 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license
PY - 2024/12/7
Y1 - 2024/12/7
N2 - Background: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides a comprehensive assessment of health and risk factor trends at global, regional, national, and subnational levels. This study aims to examine the burden of diseases, injuries, and risk factors in the USA and highlight the disparities in health outcomes across different states. Methods: GBD 2021 analysed trends in mortality, morbidity, and disability for 371 diseases and injuries and 88 risk factors in the USA between 1990 and 2021. We used several metrics to report sources of health and health loss related to specific diseases, injuries, and risk factors. GBD 2021 methods accounted for differences in data sources and biases. The analysis of levels and trends for causes and risk factors within the same computational framework enabled comparisons across states, years, age groups, and sex. GBD 2021 estimated years lived with disability (YLDs) and disability-adjusted life-years (DALYs; the sum of years of life lost to premature mortality and YLDs) for 371 diseases and injuries, years of life lost (YLLs) and mortality for 288 causes of death, and life expectancy and healthy life expectancy (HALE). We provided estimates for 88 risk factors in relation to 155 health outcomes for 631 risk–outcome pairs and produced risk-specific estimates of summary exposure value, relative health risk, population attributable fraction, and risk-attributable burden measured in DALYs and deaths. Estimates were produced by sex (male and female), age (25 age groups from birth to ≥95 years), and year (annually between 1990 and 2021). 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws (ie, 500 random samples from the estimate's distribution). Uncertainty was propagated at each step of the estimation process.Findings: We found disparities in health outcomes and risk factors across US states. Our analysis of GBD 2021 highlighted the relative decline in life expectancy and HALE compared with other countries, as well as the impact of COVID-19 during the first 2 years of the pandemic. We found a decline in the USA's ranking of life expectancy from 1990 to 2021: in 1990, the USA ranked 35th of 204 countries and territories for males and 19th for females, but dropped to 46th for males and 47th for females in 2021. When comparing life expectancy in the best-performing and worst-performing US states against all 203 other countries and territories (excluding the USA as a whole), Hawaii (the best-ranked state in 1990 and 2021) dropped from sixth-highest life expectancy in the world for males and fourth for females in 1990 to 28th for males and 22nd for females in 2021. The worst-ranked state in 2021 ranked 107th for males (Mississippi) and 99th for females (West Virginia). 14 US states lost life expectancy over the study period, with West Virginia experiencing the greatest loss (2·7 years between 1990 and 2021). HALE ranking declines were even greater; in 1990, the USA was ranked 42nd for males and 32nd for females but dropped to 69th for males and 76th for females in 2021. When comparing HALE in the best-performing and worst-performing US states against all 203 other countries and territories, Hawaii ranked 14th highest HALE for males and fifth for females in 1990, dropping to 39th for males and 34th for females in 2021. In 2021, West Virginia—the lowest-ranked state that year—ranked 141st for males and 137th for females. Nationally, age-standardised mortality rates declined between 1990 and 2021 for many leading causes of death, most notably for ischaemic heart disease (56·1% [95% UI 55·1–57·2] decline), lung cancer (41·9% [39·7–44·6]), and breast cancer (40·9% [38·7–43·7]). Over the same period, age-standardised mortality rates increased for other causes, particularly drug use disorders (878·0% [770·1–1015·5]), chronic kidney disease (158·3% [149·6–167·9]), and falls (89·7% [79·8–95·8]). We found substantial variation in mortality rates between states, with Hawaii having the lowest age-standardised mortality rate (433·2 per 100 000 [380·6–493·4]) in 2021 and Mississippi having the highest (867·5 per 100 000 [772·6–975·7]). Hawaii had the lowest age-standardised mortality rates throughout the study period, whereas Washington, DC, experienced the most improvement (a 40·7% decline [33·2–47·3]). Only six countries had age-standardised rates of YLDs higher than the USA in 2021: Afghanistan, Lesotho, Liberia, Mozambique, South Africa, and the Central African Republic, largely because the impact of musculoskeletal disorders, mental disorders, and substance use disorders on age-standardised disability rates in the USA is so large. At the state level, eight US states had higher age-standardised YLD rates than any country in the world: West Virginia, Kentucky, Oklahoma, Pennsylvania, New Mexico, Ohio, Tennessee, and Arizona. Low back pain was the leading cause of YLDs in the USA in 1990 and 2021, although the age-standardised rate declined by 7·9% (1·8–13·0) from 1990. Depressive disorders (56·0% increase [48·2–64·3]) and drug use disorders (287·6% [247·9–329·8]) were the second-leading and third-leading causes of age-standardised YLDs in 2021. For females, mental health disorders had the highest age-standardised YLD rate, with an increase of 59·8% (50·6–68·5) between 1990 and 2021. Hawaii had the lowest age-standardised rates of YLDs for all sexes combined (12 085·3 per 100 000 [9090·8–15 557·1]), whereas West Virginia had the highest (14 832·9 per 100 000 [11 226·9–18 882·5]). At the national level, the leading GBD Level 2 risk factors for death for all sexes combined in 2021 were high systolic blood pressure, high fasting plasma glucose, and tobacco use. From 1990 to 2021, the age-standardised mortality rates attributable to high systolic blood pressure decreased by 47·8% (43·4–52·5) and for tobacco use by 5·1% (48·3%–54·1%), but rates increased for high fasting plasma glucose by 9·3% (0·4–18·7). The burden attributable to risk factors varied by age and sex. For example, for ages 15–49 years, the leading risk factors for death were drug use, high alcohol use, and dietary risks. By comparison, for ages 50–69 years, tobacco was the leading risk factor for death, followed by dietary risks and high BMI.Interpretation: GBD 2021 provides valuable information for policy makers, health-care professionals, and researchers in the USA at the national and state levels to prioritise interventions, allocate resources effectively, and assess the effects of health policies and programmes. By addressing socioeconomic determinants, risk behaviours, environmental influences, and health disparities among minority populations, the USA can work towards improving health outcomes so that people can live longer and healthier lives. Funding: Bill & Melinda Gates Foundation.
AB - Background: The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 provides a comprehensive assessment of health and risk factor trends at global, regional, national, and subnational levels. This study aims to examine the burden of diseases, injuries, and risk factors in the USA and highlight the disparities in health outcomes across different states. Methods: GBD 2021 analysed trends in mortality, morbidity, and disability for 371 diseases and injuries and 88 risk factors in the USA between 1990 and 2021. We used several metrics to report sources of health and health loss related to specific diseases, injuries, and risk factors. GBD 2021 methods accounted for differences in data sources and biases. The analysis of levels and trends for causes and risk factors within the same computational framework enabled comparisons across states, years, age groups, and sex. GBD 2021 estimated years lived with disability (YLDs) and disability-adjusted life-years (DALYs; the sum of years of life lost to premature mortality and YLDs) for 371 diseases and injuries, years of life lost (YLLs) and mortality for 288 causes of death, and life expectancy and healthy life expectancy (HALE). We provided estimates for 88 risk factors in relation to 155 health outcomes for 631 risk–outcome pairs and produced risk-specific estimates of summary exposure value, relative health risk, population attributable fraction, and risk-attributable burden measured in DALYs and deaths. Estimates were produced by sex (male and female), age (25 age groups from birth to ≥95 years), and year (annually between 1990 and 2021). 95% uncertainty intervals (UIs) were generated for all final estimates as the 2·5th and 97·5th percentiles values of 500 draws (ie, 500 random samples from the estimate's distribution). Uncertainty was propagated at each step of the estimation process.Findings: We found disparities in health outcomes and risk factors across US states. Our analysis of GBD 2021 highlighted the relative decline in life expectancy and HALE compared with other countries, as well as the impact of COVID-19 during the first 2 years of the pandemic. We found a decline in the USA's ranking of life expectancy from 1990 to 2021: in 1990, the USA ranked 35th of 204 countries and territories for males and 19th for females, but dropped to 46th for males and 47th for females in 2021. When comparing life expectancy in the best-performing and worst-performing US states against all 203 other countries and territories (excluding the USA as a whole), Hawaii (the best-ranked state in 1990 and 2021) dropped from sixth-highest life expectancy in the world for males and fourth for females in 1990 to 28th for males and 22nd for females in 2021. The worst-ranked state in 2021 ranked 107th for males (Mississippi) and 99th for females (West Virginia). 14 US states lost life expectancy over the study period, with West Virginia experiencing the greatest loss (2·7 years between 1990 and 2021). HALE ranking declines were even greater; in 1990, the USA was ranked 42nd for males and 32nd for females but dropped to 69th for males and 76th for females in 2021. When comparing HALE in the best-performing and worst-performing US states against all 203 other countries and territories, Hawaii ranked 14th highest HALE for males and fifth for females in 1990, dropping to 39th for males and 34th for females in 2021. In 2021, West Virginia—the lowest-ranked state that year—ranked 141st for males and 137th for females. Nationally, age-standardised mortality rates declined between 1990 and 2021 for many leading causes of death, most notably for ischaemic heart disease (56·1% [95% UI 55·1–57·2] decline), lung cancer (41·9% [39·7–44·6]), and breast cancer (40·9% [38·7–43·7]). Over the same period, age-standardised mortality rates increased for other causes, particularly drug use disorders (878·0% [770·1–1015·5]), chronic kidney disease (158·3% [149·6–167·9]), and falls (89·7% [79·8–95·8]). We found substantial variation in mortality rates between states, with Hawaii having the lowest age-standardised mortality rate (433·2 per 100 000 [380·6–493·4]) in 2021 and Mississippi having the highest (867·5 per 100 000 [772·6–975·7]). Hawaii had the lowest age-standardised mortality rates throughout the study period, whereas Washington, DC, experienced the most improvement (a 40·7% decline [33·2–47·3]). Only six countries had age-standardised rates of YLDs higher than the USA in 2021: Afghanistan, Lesotho, Liberia, Mozambique, South Africa, and the Central African Republic, largely because the impact of musculoskeletal disorders, mental disorders, and substance use disorders on age-standardised disability rates in the USA is so large. At the state level, eight US states had higher age-standardised YLD rates than any country in the world: West Virginia, Kentucky, Oklahoma, Pennsylvania, New Mexico, Ohio, Tennessee, and Arizona. Low back pain was the leading cause of YLDs in the USA in 1990 and 2021, although the age-standardised rate declined by 7·9% (1·8–13·0) from 1990. Depressive disorders (56·0% increase [48·2–64·3]) and drug use disorders (287·6% [247·9–329·8]) were the second-leading and third-leading causes of age-standardised YLDs in 2021. For females, mental health disorders had the highest age-standardised YLD rate, with an increase of 59·8% (50·6–68·5) between 1990 and 2021. Hawaii had the lowest age-standardised rates of YLDs for all sexes combined (12 085·3 per 100 000 [9090·8–15 557·1]), whereas West Virginia had the highest (14 832·9 per 100 000 [11 226·9–18 882·5]). At the national level, the leading GBD Level 2 risk factors for death for all sexes combined in 2021 were high systolic blood pressure, high fasting plasma glucose, and tobacco use. From 1990 to 2021, the age-standardised mortality rates attributable to high systolic blood pressure decreased by 47·8% (43·4–52·5) and for tobacco use by 5·1% (48·3%–54·1%), but rates increased for high fasting plasma glucose by 9·3% (0·4–18·7). The burden attributable to risk factors varied by age and sex. For example, for ages 15–49 years, the leading risk factors for death were drug use, high alcohol use, and dietary risks. By comparison, for ages 50–69 years, tobacco was the leading risk factor for death, followed by dietary risks and high BMI.Interpretation: GBD 2021 provides valuable information for policy makers, health-care professionals, and researchers in the USA at the national and state levels to prioritise interventions, allocate resources effectively, and assess the effects of health policies and programmes. By addressing socioeconomic determinants, risk behaviours, environmental influences, and health disparities among minority populations, the USA can work towards improving health outcomes so that people can live longer and healthier lives. Funding: Bill & Melinda Gates Foundation.
UR - http://www.scopus.com/inward/record.url?scp=85210684664&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(24)01446-6
DO - 10.1016/S0140-6736(24)01446-6
M3 - Article
C2 - 39645376
AN - SCOPUS:85210684664
SN - 0140-6736
VL - 404
SP - 2314
EP - 2340
JO - The Lancet
JF - The Lancet
IS - 10469
ER -